An innovative Biotech company About Us
First-in-class disease-modifying products Discover our science
Therapies for neurodegenerative & traumatic disorders Our Pipeline
NX210 A multifunctional peptide GMP manufactured Our Products

We are dedicated

to develop drugs for neurological disorders


Our vocation is to develop first-in-class innovative drugs to treat patients with traumatic or severe neurological disorders with high unmet medical needs.


Our ambition is to improve the recovery of the functionality and the quality of life of patients.



Our Discovery

During embryogenesis, a small organ named Subcommisural Organ (SCO) located in the dorsal roof of the brain differentiates and secrets the SCO-spondin, a large multi-domain protein widely distributed in the CNS and with potent activity during neurogenesis.

Our products are small peptides derived fro

Learn more

Our Products

NX210 and analogs are first-in-class multi-target patented peptides with high potential in many CNS disorders, as demonstrated via its distinctive and multifunctional mechanism of action on neural cells, encompassing:

  • Neuroprotection with strong anti-oxidative properties & anti-apoptotic activities
Learn more

Diseases focus

Neurological disorders are diseases of the central and peripheral nervous system. These disorders are of major clinical problems with unmet medical needs and currently no satisfactory treatment.

Learn more


NEURONAX will Present the Pre-Clinical Results of its Lead Product NX210 at Neuroscience 2018

Lyon & Saint-Beauzire, France, October 28th, 2018 – NEURONAX, the biopharmaceutical company dedicated to develop first-in-class disease-modifying drugs to treat patients with neurodegenerative or traumatic neurological disorders, will present its pre-clinical results highlighting the strong potential of its lead product NX210 during SfN‘s 48th annual meeting, Neuroscience 2018, the world’s … Read more